United States securities and exchange commission logo

                          November 22, 2021

       Mark Litton, Ph.D.
       Chief Executive Officer
       Athira Pharma, Inc.
       18706 North Creek Parkway
       Suite 104
       Bothell, WA 98011

                                                        Re: Athira Pharma, Inc.
Statement on Form S-3
                                                            Filed November 15,
                                                            File No. 333-261073

       Dear Dr. Litton:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact
Christine Westbrook at 202-551-5019 with any questions.


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Bryan King, Esq.